Antagonists of IAP function such as those used in this study may therefore represent a potential antitumor strategy to overcome necrosis resistance activated by TLR3 agonists for instance in Epstein-Barr virus (EBV)-induced epithelial cancers (nasopharyngeal carcinoma) (Iwakiri et al., 2009). This evidence concerns the gene TLR3 and nasopharyngeal carcinoma.